This contract involves the ongoing supply of the medication Belimumab (L04AA26) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver the medication in accordance with the specified procurement conditions.
Tender closed on 25 Sept 2025. Awaiting award.
No single supplier dominates the field.
In healthcare medical, RHEUMATOLOGY INSTITUTE has awarded 4 contracts to 4 suppliers.
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This contract involves the ongoing supply of specific medications as outlined in Appendix 1 of the Purchase Agreement – Price Offer. The required medications include methotrexate (L04AX03), leflunomide (L04AA13), and hydroxychloroquine (P01BA02). Suppliers must adhere to the procurement conditions a
This contract involves the ongoing supply of medications as outlined in Appendix 1 of the Purchase Agreement – Price Offer. The supplies must include the pharmaceutical product Denosumab (M05BX04) in accordance with the tender conditions.
This contract involves the ongoing supply of the medication Certolizumab (L04AB05) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver the medication in accordance with the specified procurement conditions.
This contract involves the ongoing supply of the medication Etanercept (L04AB01) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver these pharmaceutical products in accordance with the specified procurement conditions.
Procurement of seasonal influenza vaccine from qualified suppliers for immunization and public health programs.
Opportunity to become a pathology testing services provider through a Provider Selection Regime process.
Seeking qualified providers to deliver pathology testing services through a Provider Selection Regime process.
Bristol NHS Foundation Trust is procuring a managed service provider to deliver comprehensive lung cancer screening services across the SWAG region from April 2027 for up to 60 months.
